First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

(2014) A. K. Gopal et al.   BLOOD

Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer

(2014) J Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Next Generation of Antibody Drug Conjugates

(2014) Fiona Mack et al.   SEMINARS IN ONCOLOGY

Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper

(2013) Boris Gorovits et al.   Bioanalysis

Novel detection of DNA-alkylated adducts of antibody–drug conjugates with potentially unique preclinical and biomarker applications

(2013) Lourdes Thevanayagam et al.   Bioanalysis

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Conjugate Therapeutics: Challenges and Potential

(2011) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker

(2008) E. Oflazoglu et al.   CLINICAL CANCER RESEARCH

Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

(2008) J. A. McEarchern et al.   CLINICAL CANCER RESEARCH

CD70 as a therapeutic target in human malignancies

(2008) Iqbal S Grewal   EXPERT OPINION ON THERAPEUTIC TARGETS

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

(2008) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS